Literature DB >> 25747454

Intestinal behavior of the ester prodrug tenofovir DF in humans.

Sophie Geboers1, Steven Haenen1, Raf Mols1, Joachim Brouwers1, Jan Tack2, Pieter Annaert1, Patrick Augustijns3.   

Abstract

Tenofovir-disoproxil-fumarate (TDF) is a double ester prodrug which enables intestinal uptake of tenofovir (TFV) after oral administration in humans. In this study, prodrug stability was monitored in situ in the human intestine and in vitro using biorelevant media. In fasted state human intestinal fluids, the prodrug was completely degraded within 90 min, resulting in the formation of the mono-ester intermediate and TFV; in fed state intestinal fluids, the degradation rate of TDF was slightly reduced and no TFV was formed. Intestinal fluid samples aspirated after administration of TDF confirmed extensive intraluminal degradation of TDF in fasted state conditions; a relatively fast absorption of TDF partly compensated for the degradation. Although food intake reduced intestinal degradation, the systemic exposure was not proportionally increased. The lower degradation in fed state conditions may be attributed to competing esterase substrates present in food, lower chemical degradation in the slightly more acidic environment and micellar entrapment, delaying exposure to the "degrading" intestinal environment. The results of this study demonstrate premature intestinal degradation of TDF and suggest that TFV may benefit from a more stable prodrug approach; however, fast absorption may compensate for fast degradation, indicating that prodrug selection should not be limited to stability assays.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical trial; Ester prodrug; Human intestinal fluids; Intestinal absorption behavior; Tenofovir

Mesh:

Substances:

Year:  2015        PMID: 25747454     DOI: 10.1016/j.ijpharm.2015.03.002

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.

Authors:  Kristina M Brooks; Jose R Castillo-Mancilla; Joshua Blum; Ryan Huntley; Samantha MaWhinney; Keisha Alexander; Becky Jo Kerr; Lucas Ellison; Lane R Bushman; Christine E MacBrayne; Peter L Anderson; Jennifer J Kiser
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

2.  Multipurpose tenofovir disoproxil fumarate electrospun fibers for the prevention of HIV-1 and HSV-2 infections in vitro.

Authors:  Kevin M Tyo; Hung R Vuong; Danial A Malik; Lee B Sims; Houda Alatassi; Jinghua Duan; Walter H Watson; Jill M Steinbach-Rankins
Journal:  Int J Pharm       Date:  2017-08-07       Impact factor: 5.875

3.  Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Authors:  Cindy J Bednasz; Charles S Venuto; Qing Ma; Eric S Daar; Paul E Sax; Margaret A Fischl; Ann C Collier; Kimberly Y Smith; Camlin Tierney; Edward P Acosta; Donald E Mager; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

4.  Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus.

Authors:  Sarah C Mann; Mary Morrow; Ryan P Coyle; Stacey S Coleman; Austin Saderup; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson; Jose R Castillo-Mancilla
Journal:  J Acquir Immune Defic Syndr       Date:  2020-12-01       Impact factor: 3.771

5.  Development of a Novel Formulation That Improves Preclinical Bioavailability of Tenofovir Disoproxil Fumarate.

Authors:  Melynda E Watkins; Steve Wring; Ryan Randolph; Seonghee Park; Kendall Powell; Lissa Lutz; Michelle Nowakowski; Ram Ramabhadran; Paul L Domanico
Journal:  J Pharm Sci       Date:  2016-12-14       Impact factor: 3.534

6.  Strawberry Decreases Intraluminal and Intestinal Wall Hydrolysis of Testosterone Undecanoate.

Authors:  Atheer Zgair; Yousaf Dawood; Suhaib M Ibrahem; Jong Bong Lee; Wanshan Feng; Peter M Fischer; Pavel Gershkovich
Journal:  Molecules       Date:  2021-01-05       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.